Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | PRKDC | P78527 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25721192 | 0.91 | LMNA (0.53) | LMNAPOLBHTTCYP3A4L3MBTL1 | |
| SCHEMBL12937577 | 0.89 | LMNA (0.50) | LMNAPOLBHTTCYP3A4L3MBTL1 | |
| SCHEMBL14685517 | 0.89 | LMNA (0.51) | LMNAPOLBHTTCYP3A4L3MBTL1 | |
| SCHEMBL13246590 | 0.86 | HTT (0.52) | LMNAPOLBHTTCYP3A4L3MBTL1 | |
| SCHEMBL2605630 | 0.86 | LMNA (0.73) | LMNAPOLBHTTCYP3A4L3MBTL1 | |
| SCHEMBL375897 | 0.84 | PKM (0.59) | LMNAPOLBHTTCYP3A4L3MBTL1 | |
| SCHEMBL30716507 | 0.84 | L3MBTL1 (0.59) | LMNAPOLBHTTCYP3A4L3MBTL1 | |
| SCHEMBL28557642 | 0.84 | LMNA (0.58) | LMNAPOLBHTTCYP3A4L3MBTL1 | |
| SCHEMBL4108486 | 0.84 | L3MBTL1 (0.59) | LMNAPOLBHTTCYP3A4L3MBTL1 | |
| SCHEMBL31549975 | 0.84 | PKM (0.59) | LMNAPOLBHTTCYP3A4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807628-B2 | Benzodiazepine derivatives and uses thereof | INTOCELL, INC. (KR) | 2023-11-07 | — | — | US | disclosed |
| US-20230190939-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | INTOCELL, INC. (KR) | 2023-06-22 | — | — | US | disclosed |
| US-20170022174-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PROTAMED INC (US) | 2017-01-26 | — | — | US | disclosed |
| US-9334251-B2 | Compounds for the treatment of neurodegenerative diseases | PROTAMED, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150274681-A1 | Compounds for the treatment of Neurodegenerative Diseases | PROTEOTECH INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-9085549-B2 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC (US) | 2015-07-21 | — | — | US | disclosed |
| US-20150011604-A1 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8865754-B2 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20120251448-A1 | Compounds for Use in the Detection of Neurodegenerative Diseases | AVID RADIOPHARMACEUTICALS, INC. | 2012-10-04 | — | — | US | disclosed |
| WO-2012118935-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PROTEOTECH INC (US) | 2012-09-07 | — | — | WO | disclosed |
| US-20070004784-A1 | Sulfonamides as potassium channel blockers | ICAGEN, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004784-A1 | Sulfonamides as potassium channel blockers | ICAGEN, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| CN-1143855-C | I (ortho)-anthranilamide derivatives as anti-coagulants | ���ֹɷݹ�˾ | 2004-03-31 | — | — | CN | disclosed |
| EP-1040108-B1 | ORTHO-ANTHRANILAMIDE DERIVATIVES AS ANTI-COAGULANTS | SCHERING AG (DE) | 2004-02-25 | — | — | EP | disclosed |
| US-6498185-B1 | ENZYME FACTOR XA INHIBITORS | BERLEX LABORATORIES, INC. | 2002-12-24 | — | — | US | disclosed |
| US-6380221-B1 | FOR THERAPY OF DISEASE-STATES CHARACTERIZED BY THROMBOTIC ACTIVITY | BERLEX LABORATORIES, INC. | 2002-04-30 | — | — | US | disclosed |
| CN-1282329-A | I (ortho)-anthranilamide derivatives as anti-coagulants | SCHERING AG (DE) | 2001-01-31 | — | — | CN | disclosed |
| US-6140351-A | FOR TREATING THROMBOSIS | BERLEX LABORATORIES, INC. (US) | 2000-10-31 | — | — | US | disclosed |
| EP-1040108-A1 | ORTHO-ANTHRANILAMIDE DERIVATIVES AS ANTI-COAGULANTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999032477-A1 | ORTHO-ANTHRANILAMIDE DERIVATIVES AS ANTI-COAGULANTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190939-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | CD47, ENPP2, CD2 | LMNA 3409/4885POLB 4384/4885HTT 1445/4885 |
| US-11807628-B2 | Benzodiazepine derivatives and uses thereof | GABRB3, GABRB2, GABRB1 | LMNA 726/4885POLB 1661/4885HTT 329/4885 |
| US-20150274681-A1 | Compounds for the treatment of Neurodegenerative Diseases | PSEN1, PSEN2, GRN | LMNA 1777/4885POLB 2427/4885HTT 16/4885 |
| US-20150011604-A1 | Compounds for the treatment of neurodegenerative diseases | SNCA, MAPT, PARK7 | LMNA 2269/4885POLB 1166/4885HTT 4/4885 |
| US-20120251448-A1 | Compounds for Use in the Detection of Neurodegenerative Diseases | SNCA, PARK7, NLN | LMNA 1212/4885POLB 1623/4885HTT 7/4885 |
| US-20170022174-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PSEN1, PSEN2, GRN | LMNA 1777/4885POLB 2427/4885HTT 16/4885 |
| US-20070004784-A1 | Sulfonamides as potassium channel blockers | KCNJ2, KCNJ1, KCNJ11 | LMNA 2706/4885POLB 2287/4885HTT 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.